Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.

WASHINGTON, DC - SEPTEMBER 28, 2013: Federal Trade Commission Building in Washington, DC.

The Federal Trade Commission's global settlement with Teva Pharmaceutical Industries Ltd. is a victory for the agency in its campaign to eliminate so-called pay-for-delay deals between brand and generic companies that include side deals and commitments by the brand not to launch an authorized generic.

The settlement, announced Feb. 19, resolves claims against Teva in three pending FTC antitrust lawsuits and expands the terms in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics